Insight

Jun 8, 2024, 05:20

Mohammad Jad Moussa: ASCO24 Proceedings – GTA as a Nephron-Sparing ‘Bridging’ Strategy

Mohammad Jad Moussa, Postdoc Fellow of GU Oncology at MD Anderson Cancer Center, shared a post on X:

“From ASCO24 Proceedings: GTA as a Nephron-Sparing ‘Bridging‘ Strategy Before Cisplatin-Based Regimens in Metastatic UC.

Matt Campbell and Omar Alhalabi at MD Anderson Cancer Center GUSM.

Joint Work with terrific residents at UTHealth Houston IM Residency, BCM IM Residency.

Why: ADCs not accessible to all patients, chemo data remains crucial for many patients and oncologists.
Who: n=76, 1L LA/mUC, 63% prior nephrostomy/ureteral stenting, 72% started on GTA due to tumor-related renal insufficiency.
What: High GFR +11.2 mL/min [95% CI, 7.4-14.9] with GTA, 23% (16/69) received cisplatin post-GTA, mOS 11.3 months.”

Visit the article website.
Source: Mohammad Jad Moussa/X

ADC ASCO24 BCM IM Residency cancer chemo chemotherapy Cisplatin-Based Regimens in Metastatic UC High GFR Matt Campbell MD Anderson Cancer Center Mohammad Jad Moussa nephrostomy/ureteral stenting Omar Alhalabi OncoDaily Oncology tumor-related renal insufficiency UTHealth Houston IM Residency

Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 10

OncoThon 2024 Raises $1.3 Million for Pediatric Cancer Research

Richard Sullivan: Do we need a 'new' Geneva Convention and protocols?

Remembering Virgil Abloh: Louis Vuitton’s Creative Director Honored at 41 After His Brave Battle with Cardiac Angiosarcoma

Special Coverage